Education
About Us
Working with TipRanks
Follow Us
NRX Pharmaceuticals (NRXP)
NASDAQ:NRXP
NRXP Stock Chart & Stats
$3.05
-$0.69(-14.70%)
At close: 4:00 PM EST
$3.05
-$0.69(-14.70%)
Day’s Range― - ―
52-Week Range$1.12 - $6.01
Previous CloseN/A
Volume2.07M
Average Volume (3M)475.66K
Market Cap
$72.50M
Enterprise Value$65.79M
Total Cash (Recent Filing)$2.91M
Total Debt (Recent Filing)$10.23M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Nov 17, 2025EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.98
Shares Outstanding23,769,901
10 Day Avg. Volume509,446
30 Day Avg. Volume475,656
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue16.45K
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.95
Forecast
1Y Price Target
$33.00Price Target Upside981.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Product DevelopmentNRx Pharmaceuticals has refiled an Abbreviated New Drug Application (ANDA) for KETAFREE, their preservative-free ketamine, which could benefit from priority review due to the national drug shortage of ketamine.
Regulatory ApprovalsFDA’s approval of UZEDY underscores a more flexible, data-integrated regulatory stance in psychiatry—directly supportive of NRx’s filing strategy for NRX-100 and NRX-101.
Regulatory SupportThe FDA’s actions reinforce a clear policy direction toward addressing suicidality and serious mood disorders as public health priorities—a stance that aligns with NRx-100’s expanded Fast Track designation.
Bears Say
NRX Pharmaceuticals News
NRXP FAQ
What was NRX Pharmaceuticals’s price range in the past 12 months?
NRX Pharmaceuticals lowest stock price was $1.12 and its highest was $6.01 in the past 12 months.
What is NRX Pharmaceuticals’s market cap?
NRX Pharmaceuticals’s market cap is $72.50M.
When is NRX Pharmaceuticals’s upcoming earnings report date?
NRX Pharmaceuticals’s upcoming earnings report date is Nov 17, 2025 which is in 18 days.
How were NRX Pharmaceuticals’s earnings last quarter?
NRX Pharmaceuticals released its earnings results on Aug 18, 2025. The company reported -$0.98 earnings per share for the quarter, missing the consensus estimate of -$0.15 by -$0.83.
Is NRX Pharmaceuticals overvalued?
According to Wall Street analysts NRX Pharmaceuticals’s price is currently Undervalued.
Does NRX Pharmaceuticals pay dividends?
NRX Pharmaceuticals does not currently pay dividends.
What is NRX Pharmaceuticals’s EPS estimate?
NRX Pharmaceuticals’s EPS estimate is 0.02.
How many shares outstanding does NRX Pharmaceuticals have?
NRX Pharmaceuticals has 23,769,901 shares outstanding.
What happened to NRX Pharmaceuticals’s price movement after its last earnings report?
NRX Pharmaceuticals reported an EPS of -$0.98 in its last earnings report, missing expectations of -$0.15. Following the earnings report the stock price went down -9.42%.
Which hedge fund is a major shareholder of NRX Pharmaceuticals?
Currently, no hedge funds are holding shares in NRXP
NRX Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.00 (981.97% Upside)
$33.00 (981.97% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.8%
Last 30 Days ▲ 32.6%
Last 30 Days ▲ 32.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
164.80%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.09%
Trailing 12-Months
Company Description
NRX Pharmaceuticals
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
NRXP Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in drug development, financial management, and strategic partnerships, with a strong focus on advancing key drug applications and developing the Hope Therapeutics network. Despite increased net losses and regulatory challenges, the company's strategic moves and financial improvements suggest a positive outlook.View all NRXP earnings summariesNRXP Stock 12 Month Forecast
Average Price Target
$33.00
▲(981.97% Upside)
Technical Analysis
CervoMed
―
Coeptis Therapeutics Holdings
―
Werewolf Therapeutics
―
OKYO Pharma Limited Sponsored ADR
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
15.88% Insiders
2.40% Mutual Funds
<0.01% Other Institutional Investors
78.11% Public Companies and Individual Investors